Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD

The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, CA, and brought together experts in the field, who discussed several fascinating topics, including novel treatment strategies in multiple myeloma, the prognostic value of measurable residual disease (MRD), managing patients with high-risk disease, and more.

In this exclusive podcast, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, and Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, hold a fascinating discussion on the management of high-risk patients, highlighting data from several UK clinical trials. The experts also discuss the prognostic value of MRD and its application in clinical practice, the management of frail patients, and further comment on the recent approval of teclistamab by the European Medicines Agency (EMA).

The post Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD appeared first on VJHemOnc.